he attended the london school of economics he joined glaxo in 1965 as a financial controller he became finance director in 1968 when aged 42 in april 1980 it was announced that he would become chief executive in the early 1980s glaxo briefly surpassed british telecom to become britain s most valued company on the stock market lse and glaxo was the world s second largest pharmaceutical company and remained so into the 1990s it had been 25th largest in the world in 1980 the reasons for this were a huge increase in its r d budget and employing many more researchers by 1993 it was spending 750 million on research with around 5 500 researchers of which 3 500 were in the uk its other researchers were in italy the us and japan in april 1985 he was appointed as deputy chairman and it was announced that he would be leaving his post as chief executive in early 1986 on 10 december 1985 he became chairman of glaxo he left as chairman in november 1994 when aged 68 glaxo merged to become glaxo wellcome a year later in 1995 glaxo drugs that sold well included the fortum ceftazidime and